Information Provided By: 
Fly News Breaks for June 15, 2018
BPMC, DCPH
Jun 15, 2018 | 11:47 EDT
Piper Jaffray analyst Christopher Raymond said that Blueprint Medicines (BPMC) presented "impressive efficacy data" at the EHA meeting on BLU-285 in systemic mastocytosis, leading him to think this mechanism in SM continues to make sense. With comparable efficacy data in advanced GIST and, importantly, a better safety profile, he thinks Deciphera's (DCPH) DCC-2618 may "stack up well" against Blueprint's BLU-285, Raymond tells investors. He maintains an Overweight rating and $50 price target on Deciphera shares.
News For DCPH;BPMC From the Last 2 Days
There are no results for your query DCPH;BPMC
